Argatroban for anticoagulation during cardiopulmonary bypass in an infant

Paediatric Anaesthesia

Volumn 15, Issue 4, 2005, Pages 328-333

  Dyke II, Peter C ^a   Russo, Pierantonio ^b   Mureebe, Leila ^b   Russo, Joanne ^b   Tobias, Joseph D ^a,c,d  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Pediat Critical Care/Pediat A ^*  (United States)

^d Pediatric Intensive Care Medicine   (United States)

Author keywords

Anti coagulation; Argatroban; Cardiopulmonary bypass; Heparin induced thrombocytopenia

Indexed keywords

ABCIXIMAB; ANCROD; ANTIBIOTIC AGENT; ARGATROBAN; ATRACURIUM; DALTEPARIN; DESFLURANE; ENOXAPARIN; EPTIFIBATIDE; FENTANYL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HEPARINOID; HIRUDIN; HIRULOG; LEPIRUDIN; RECOMBINANT HIRUDIN; SEVOFLURANE; THROMBIN INHIBITOR; TIROFIBAN;

ANTICOAGULATION; ARTICLE; BACTERIAL ENDOCARDITIS; BLEEDING; CARDIOPULMONARY BYPASS; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; INFANT; PRIORITY JOURNAL; TRICUSPID VALVE DISEASE;

ANTI-BACTERIAL AGENTS; ANTIBODIES; ANTICOAGULANTS; CARDIOPULMONARY BYPASS; DRUG HYPERSENSITIVITY; ENDOCARDITIS, BACTERIAL; HEPARIN; HEPATOMEGALY; HUMANS; INFANT; INTRAOPERATIVE COMPLICATIONS; MALE; PIPECOLIC ACIDS; SPLENOMEGALY; THROMBOCYTOPENIA; TRICUSPID VALVE;

EID: 16244418701     PISSN: 11555645     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2005.01417.x     Document Type: Article

References (38)

1. Mureebe L, Silver D. Heparin-induced thrombocytopenia: pathophysiology and management. Vasc Endo Surg 2002; 36: 163-170.
2. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 2121-2131.
3. Von Segesser LK, Mueller X, Horisberger J et al. Alternatives to unfractioned heparin for anticoagulation in cardiopulmonary bypass. Perfusion 2001; 16: 411-416.
4. Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced thrombodytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 2nd edn. New York: Marcel Dekker, 2001: 381-407.
5. Okamoto S, Hijikata A, Kikumoto R et al. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805: the importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-446.
6. Sakai M, Ohteki H, Narita Y et al. Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model. Cardiovasc Surg 1999; 7: 187-194.
7. Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of Argatroban. J Thromb Thrombolysis 2001; 12: 141-149.
8. Swan SK. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329.
9. Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003; 75: 1622-1624.
10. Furukawa K, Ohteki H, Hirabara K et al. The use of Argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg 2001; 122: 1255-1256.
11. Kieta DR, McCammon AT, Holman WL et al. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 2003; 96: 956-958.
12. Lubenow N, Greinacher A. Hirudin in heparin-induced thrombocytopenia. Sem Thromb Hemost 2002; 28: 431-438.
13. Ohteki H, Furukawa K, Ohnishi H et al. Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg 2000; 48: 39-46.
14. Cetta F, Graham LC, Wrona LL et al. Argatroban use during pediatric interventional cardiac catheterization. Catheter Cardiovasc Interv 2004; 61: 147-149.
15. Herrman JR, Suryapranata H, den Heijer P et al. Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study. J Thromb Thrombolys 1996; 3: 367-375.
16. Kawada T, Kitagawa H, Hoson M et al. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hem Onc Clin N Am 2000; 14: 445-457.
17. Malherbe S, Tsui BCH, Stobart K et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004; 100: 443-445.
18. Tran JQ, Ci Cicco RA, Sheth SB et al. Assessment of the potential pharmacokinetics and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999; 39: 513-519.
19. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001; 72: S1814-S1820.
20. Koster A, Loebe M, Mertzlufft F et al. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg 2000; 70: 2160-2161.
21. Mak KH, Kottke-Marchant K, Brooks LM et al. In vitro effect of platelet glycoprotein Iib/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia. Thromb Haemost 1998; 80: 989-993.
22. Jeske WP, Walenga JM, Szatkowski E et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997; 88: 271-281.
23. Severin T, Zieger B, Sutor AH. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Sem Thromb Hemost 2002; 28: 447-454.
24. Vasquez JC, Vichiendilokkul A, Mahmood S et al. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 2002; 74: 2177-2179.
25. Davis Z, Anderson R, Short D et al. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 2003; 75: 264-265.
26. Latham P, Revelis AF, Joshi GP et al. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anaesthesia 2000; 92: 263-266.
27. Koster A, Kuppe H, Crystal GJ et al. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesth Analg 2000; 90: 292-298.
28. Koster A, Kuppe H, Hetzer R et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 1998; 89: 777-780.
29. Nuttall GA, Oliver WC, Santrach PJ et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 2003; 96: 344-350.
30. Nowak G. Pharmacology of recombinant hirudin. Sem Throtnb Hemost 2002; 28: 415-423.
31. Fischer GK. Hirudin in renal insufficiency. Sem Thromb Hemost 2002; 28: 467-482.
32. Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Sem Throm Hemost 2002; 28: 425-430.
33. Gillis S, Merin G, Zahger D et al. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haem 1997; 98: 657-659.
34. Saxon BR, Black MD, Edgell D et al. Pediatric heparin-induced thrombocytopenia: management with danaparoid (Orgaran). Ann Thorac Surg 1999; 68: 1076-1078.
35. Olin DA, Urdaneta F, Lobato E. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. J Cardio Vasc Anesth 2000; 14: 707-709.
36. Kanagasabay RR, Unsworth-White MJ, Robinson G et al. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia. Ann Thorac Surg 1998; 66: 567-569.
37. Spiess BD, Gernsheimer T, Vocelka C et al. Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation. J Cardio Vasc Anesth 1996; 10: 918-921.
38. Smith RE, Townsend GE, Berry BR et al. Enoxaparin for unstable angina and ancrod for cardiac surgery following heparin allergy. Ann Pharmacother 1996; 30: 476-480.